ARS Pharmaceuticals, Inc (SPRY) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for ARS Pharmaceuticals, Inc (US:SPRY), trading at 5.63. In 2025, ARS Pharmaceuticals, Inc generated $84.28 Million in revenue and -$171.21 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for ARS Pharmaceuticals, Inc is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: 5.63
- Recent Revenue (2025): $84.28 Million
- Free Cash Flow (2025): -$171.21 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.